Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2

Blood Pressure
T EkbomB Scherstén

Abstract

To perform a subgroup analysis on those patients in STOP-Hypertension-2 who had isolated systolic hypertension. The STOP-Hypertension-2 study evaluated cardiovascular mortality and morbidity in elderly hypertensives comparing treatment with conventional drugs (diuretics, beta-blockers) with that of newer ones [angiotensin-converting enzyme (ACE) inhibitors, calcium antagonists]. In all, 6614 elderly patients with hypertension (mean age 76.0 years, range 70-84 years at baseline) were included in STOP-Hypertension-2. In the present subgroup analysis of STOP-Hypertension-2, isolated systolic hypertension was defined as systolic blood pressure at least 160 mmHg and diastolic blood pressure below 95 mmHg, in accordance with the Syst-Eur and Syst-China study criteria. In total, 2280 patients in STOP-Hypertension-2 met these criteria. In the study, patients were randomized to one of three treatment groups: "conventional" antihypertensive therapy with beta-blockers or diuretics (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or fixed-ratio hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily); ACE inhibitors (enalapril 10 mg or lisinopril 10 mg daily); or calcium antagonists (felodipine 2.5 mg or isradipine 2.5 mg daily). Analysis ...Continue Reading

Citations

Oct 27, 2015·Journal of Internal Medicine·D A Butt, P J Harvey
Jul 22, 2008·The American Journal of Medicine·Laura Pedelty, Philip B Gorelick
Aug 27, 2005·British Journal of Clinical Pharmacology·Mike Schachter
Feb 1, 2008·The Journal of Clinical Hypertension·Joel M Neutel, Lawrence I Gilderman
Nov 18, 2005·Pharmacology & Therapeutics·G Cohuet, H Struijker-Boudier
Feb 8, 2005·Cardiology Clinics·Kris Vijayaraghavan, Prakash C Deedwania
Oct 26, 2016·The American Journal of Medicine·Chirag BavishiFranz H Messerli
May 15, 2008·Cerebrovascular Diseases·UNKNOWN European Stroke Organisation (ESO) Executive Committee, UNKNOWN ESO Writing Committee
Apr 27, 2005·Hypertension·Carmen A PeraltaMichael G Shlipak
Apr 10, 2008·Journal of Hypertension·Dimitris P Papadopoulos, Vasilios Papademetriou
Oct 18, 2014·Drugs & Aging·Leah M GoeresDavid S H Lee
Nov 27, 2014·Journal of Hypertension·Giuseppe Mancia, Cristina Giannattasio
Jun 26, 2020·Expert Opinion on Pharmacotherapy·Fabio AngeliGianpaolo Reboldi
Jul 25, 2017·The Journal of Clinical Hypertension·Ming DengXiao-Shu Cheng
Nov 6, 2004·Current Hypertension Reports·Gary E Sander
May 17, 2007·Joint Commission Journal on Quality and Patient Safety·Christianne L RoumieTheodore Speroff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.